Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)

Trial Profile

Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Nov 2018

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms FARAONIC
  • Sponsors Bayer
  • Most Recent Events

    • 19 Nov 2018 Planned End Date changed from 30 Nov 2020 to 30 Dec 2020.
    • 19 Nov 2018 Planned primary completion date changed from 30 Sep 2020 to 30 Nov 2020.
    • 10 Aug 2018 Planned End Date changed from 30 Aug 2020 to 30 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top